Gynaecomastia and hair loss are two conditions that, when they occur together in males, may point towards an underlying hormonal imbalance — though they can also arise independently. Both involve sensitivity to sex hormones: breast glandular tissue responds to the oestrogen-to-testosterone ratio, whilst hair follicles are highly sensitive to dihydrotestosterone (DHT). Understanding the potential link between these symptoms is important for timely diagnosis and appropriate management. This article explores the hormonal mechanisms, common causes, relevant medications, and treatment options available in the UK, including NHS pathways and when to seek urgent medical advice.

Understanding Gynaecomastia and Hair Loss as Linked Symptoms

Gynaecomastia and hair loss may share a hormonal basis, as breast glandular tissue responds to oestrogen-to-testosterone ratios and hair follicles are sensitive to DHT, though the two conditions frequently occur independently.

Not sure if this is normal? Chat with one of our pharmacists →

Gynaecomastia — the benign enlargement of glandular breast tissue in males — and hair loss (alopecia) may appear to be unrelated conditions at first glance. When they occur together, they may indicate an underlying hormonal imbalance, although in many individuals the two conditions arise independently and coincidentally. Both can significantly affect self-esteem and quality of life, making it important to understand their potential shared origins.

It is important to distinguish true gynaecomastia — caused by proliferation of glandular breast tissue, detectable as a firm disc of tissue beneath the nipple — from pseudogynaecomastia, which is fatty deposition in the chest without glandular involvement and is commonly associated with overweight or obesity. This distinction matters in primary care triage, as pseudogynaecomastia does not carry the same hormonal implications.

In males, breast tissue is sensitive to the ratio of oestrogen to testosterone. When this balance shifts — whether due to physiological changes, medication, or an underlying health condition — true gynaecomastia can develop. Similarly, hair follicles are highly responsive to androgens, particularly dihydrotestosterone (DHT), a potent derivative of testosterone. Disruptions in androgen levels or sensitivity can therefore affect both breast tissue and hair follicles.

However, androgenetic alopecia (male-pattern hair loss) very commonly occurs without any systemic endocrine abnormality, and scalp hair loss pattern is not a reliable indicator of systemic androgen status. The co-occurrence of gynaecomastia and hair loss is a clinically meaningful signal that warrants assessment, but it does not automatically confirm a single hormonal diagnosis. Understanding the mechanisms involved is the first step towards appropriate investigation and management.

Sources: NHS – Enlarged male breasts (gynaecomastia); NHS – Hair loss; NICE CKS – Gynaecomastia.

Common Causes and Hormonal Mechanisms Behind Both Conditions

The primary hormonal driver is a relative increase in oestrogen or decrease in testosterone; causes include hypogonadism, hyperthyroidism, liver disease, obesity, Klinefelter syndrome, and hCG-secreting tumours.

The most common hormonal driver linking gynaecomastia and hair loss is an imbalance between oestrogen and androgens. In males, a relative increase in oestrogen activity — or a decrease in testosterone — can stimulate breast glandular tissue, leading to gynaecomastia. Fluctuations in androgen levels may also influence the hair growth cycle, potentially accelerating androgenetic alopecia in genetically predisposed individuals.

Several underlying conditions can produce this hormonal disruption:

• Hypogonadism: Reduced testosterone production from the testes lowers androgen levels, increasing the relative effect of oestrogen on breast tissue.

• Hyperthyroidism: Elevated thyroid hormones may influence sex-hormone-binding globulin (SHBG) and androgen-to-oestrogen conversion, though the precise mechanism is multifactorial.

• Liver disease: The liver metabolises oestrogens; impaired liver function can lead to oestrogen accumulation.

• Obesity: Adipose tissue contains aromatase, which converts androgens to oestrogens, raising oestrogen levels in overweight individuals.

• Klinefelter syndrome (47,XXY): Associated with low testosterone and elevated oestrogen, often presenting with gynaecomastia.

• Testicular tumours and other hCG-secreting malignancies: Germ-cell tumours and other tumours can secrete human chorionic gonadotrophin (hCG), stimulating oestrogen production and causing gynaecomastia. This is an important differential that requires prompt investigation.

• Chronic kidney disease, malnutrition, and HIV: These systemic conditions are also recognised causes of gynaecomastia.

Androgenetic alopecia, the most prevalent form of hair loss in men, is driven by DHT binding to androgen receptors in scalp follicles, causing follicular miniaturisation over time. Importantly, AGA can progress independently of systemic androgen levels — it is primarily determined by genetic predisposition and local follicular sensitivity to DHT, and may continue even when serum testosterone is low or normal. This complexity underscores the importance of a thorough assessment when both symptoms are present.

Sources: NICE CKS – Gynaecomastia; NHS – Enlarged male breasts (gynaecomastia).

Medications That May Contribute to Gynaecomastia and Hair Loss

Finasteride, spironolactone, anabolic steroids, and antiandrogens are among the medications most commonly associated with both gynaecomastia and hair changes; patients should not stop prescribed medicines without medical advice.

A wide range of medications are recognised causes of drug-induced gynaecomastia, and some of these same agents can also influence hair growth. It is important to review a patient's full medication history when both symptoms are present, as iatrogenic causes are both common and potentially reversible.

Medications commonly associated with gynaecomastia include:

• Spironolactone: An aldosterone antagonist with anti-androgenic properties, used for heart failure and hypertension. It can cause gynaecomastia by blocking androgen receptors. It is also used off-label (unlicensed) for hair loss in women in the UK, where it requires monitoring including electrolytes (potassium), reflecting its complex hormonal effects.

• Finasteride and dutasteride: 5-alpha reductase inhibitors. Finasteride 1 mg is licensed in the UK for male androgenetic alopecia; finasteride 5 mg is licensed for benign prostatic hyperplasia. Dutasteride is not licensed in the UK for androgenetic alopecia. Both agents can occasionally cause gynaecomastia as a side effect by reducing DHT. Importantly, the MHRA has issued a Drug Safety Update for finasteride highlighting risks of psychiatric side effects (including depression and suicidal ideation) and sexual dysfunction (including persistent effects after stopping). Patients should be counselled about these risks before starting treatment, and any suspected adverse effects should be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

• Anabolic steroids: Misuse can suppress natural testosterone production and increase aromatisation to oestrogen, causing both gynaecomastia and paradoxical hair loss.

• Antiandrogens (e.g., bicalutamide, cyproterone acetate): Used in prostate cancer and gender-affirming care; these can cause gynaecomastia and may affect hair density.

• Cimetidine (an H2-receptor antagonist) and ketoconazole: These have a well-established association with gynaecomastia. The association with proton pump inhibitors (PPIs) is based on rare case reports only and is considered weak evidence; PPIs are not regarded as a common cause.

• Digoxin and certain antipsychotics: Also recognised as potential contributors to gynaecomastia.

The MHRA and relevant Summary of Product Characteristics (SmPC) for these medicines list gynaecomastia and hair changes among potential adverse effects. Patients should never discontinue prescribed medication without consulting their GP or specialist, as the risks of stopping treatment may outweigh the side effects. A medication review with a healthcare professional is the appropriate first step. Suspected adverse drug reactions should be reported via the MHRA Yellow Card Scheme.

Sources: MHRA Drug Safety Update – Finasteride; MHRA/SmPCs – Finasteride, Dutasteride, Spironolactone, Bicalutamide, Cyproterone acetate.

When to Seek Medical Advice and What to Expect on the NHS

Seek prompt GP assessment if you notice rapid breast enlargement, a hard unilateral breast lump, nipple discharge, or a new testicular lump, as these require urgent investigation to exclude malignancy under NICE NG12.

Individuals experiencing both gynaecomastia and hair loss should arrange an appointment with their GP, particularly if the symptoms are new, progressive, or accompanied by other changes. Whilst both conditions can be benign and self-limiting, their co-occurrence may indicate an underlying hormonal or systemic condition that requires investigation.

You should seek prompt medical advice if you notice:

• Rapid or painful breast tissue enlargement

• A hard, irregular, or one-sided breast lump, skin changes, or nipple discharge — these features require urgent assessment to exclude male breast cancer. Under NICE guideline NG12 (Suspected Cancer: Recognition and Referral), men with a unilateral, firm, subareolar mass with or without skin changes or nipple discharge should be referred urgently via the 2-week-wait pathway

• A new testicular lump, swelling, or pain — this requires urgent GP assessment and may prompt testicular ultrasound to exclude a germ-cell tumour or other hCG-secreting malignancy

• Significant or sudden hair loss, including patchy loss (which may suggest alopecia areata, an autoimmune condition)

• Associated symptoms such as fatigue, weight changes, reduced libido, or erectile dysfunction

• Symptoms arising shortly after starting a new medication

On the NHS, your GP will take a detailed history, including medication use, family history, and lifestyle factors. They will perform a physical examination and are likely to request blood tests to assess hormone levels, liver and thyroid function, and other relevant markers. Referral to an endocrinologist, dermatologist, or urologist may follow depending on the findings.

NICE CKS (Clinical Knowledge Summaries) on Gynaecomastia outlines a stepwise approach to investigation, beginning in primary care and escalating to specialist services where indicated. Waiting times for NHS dermatology and endocrinology appointments can vary by region, so early presentation is advisable. Private referral pathways are also available for those who wish to be seen more quickly.

Sources: NICE NG12 – Suspected Cancer: Recognition and Referral; NICE CKS – Gynaecomastia; NHS – Enlarged male breasts (gynaecomastia).

Diagnosis and Treatment Options Available in the UK

Diagnosis involves blood tests including testosterone, LH, FSH, oestradiol, β-hCG, thyroid, and liver function; treatment is directed at the underlying cause and may include medication review, topical minoxidil, finasteride, or surgery subject to NHS commissioning criteria.

Diagnosis of the underlying cause of gynaecomastia and hair loss typically involves a combination of clinical assessment and targeted investigations. Blood tests will usually include:

• Serum testosterone (total and free), LH, and FSH — to assess gonadal function

• SHBG (sex hormone-binding globulin) — to help interpret free androgen levels

• Oestradiol — to detect oestrogen excess

• Prolactin — elevated levels can suppress testosterone

• β-hCG (and AFP) — when a testicular tumour or other hCG-secreting malignancy is suspected

• Thyroid function tests (TFTs)

• Liver function tests (LFTs) and renal function

• Karyotype if Klinefelter syndrome is suspected

Imaging may also be indicated: testicular ultrasound when a testicular abnormality is suspected, and breast imaging when the clinical examination raises concern about malignancy. For hair loss, a dermatologist may perform a scalp examination, trichoscopy, or occasionally a scalp biopsy to distinguish between androgenetic alopecia, alopecia areata, and other forms.

Treatment is directed at the underlying cause where identified. For gynaecomastia, options include:

• Watchful waiting: Physiological gynaecomastia (e.g., in adolescence) often resolves spontaneously.

• Medication review: Discontinuing or switching a causative drug, under medical supervision.

• Tamoxifen or raloxifene: These are used off-label under specialist supervision in persistent or painful cases; they are not licensed for this indication in the UK and should only be prescribed by a specialist.

• Surgery (mastectomy): Access on the NHS depends on local Integrated Care Board (ICB) commissioning criteria. It is typically considered only after prolonged stability, failure of conservative measures, and documented significant psychological impact. Patients should discuss eligibility with their GP or specialist.

For androgenetic alopecia, NICE CKS supports considering topical minoxidil (available over the counter) and oral finasteride 1 mg (prescription only, licensed in the UK for men with AGA) as treatment options. Dutasteride is not licensed in the UK for androgenetic alopecia and its use for this indication would be off-label. Alopecia areata may be managed with corticosteroids or, in severe cases, JAK inhibitor therapy: baricitinib (Olumiant) is licensed in the UK for severe alopecia areata in adults, subject to specialist assessment and local commissioning. Treatment plans should be tailored to the individual, taking into account the cause, severity, and patient preferences.

Sources: NICE CKS – Gynaecomastia; NICE CKS – Male pattern hair loss; NICE CKS – Alopecia areata; MHRA/SmPC – Finasteride 1 mg; EMA EPAR/MHRA – Baricitinib (Olumiant).

Managing Both Conditions Safely: Lifestyle and Clinical Guidance

Maintaining a healthy weight, limiting alcohol, and avoiding anabolic steroids can support hormonal balance; suspected adverse drug reactions should be reported via the MHRA Yellow Card Scheme, and psychological support should be considered alongside medical management.

Alongside clinical treatment, certain lifestyle modifications can support hormonal balance and overall wellbeing in individuals affected by both gynaecomastia and hair loss. These measures are not a substitute for medical care but can complement prescribed treatments.

Lifestyle recommendations include:

• Maintaining a healthy body weight: Reducing excess adipose tissue lowers aromatase activity, which can help normalise the oestrogen-to-testosterone ratio and may improve both conditions.

• Limiting alcohol consumption: Alcohol can impair liver function and suppress testosterone production, both of which may worsen gynaecomastia. NHS guidance recommends drinking no more than 14 units of alcohol per week, spread over three or more days.

• Avoiding anabolic steroids and performance-enhancing drugs: These are a well-established cause of both conditions and should be avoided entirely.

• Managing stress: Chronic stress may contribute to telogen effluvium (a form of diffuse hair shedding) and affect overall wellbeing. The relationship between stress and testosterone suppression is less direct; stress management is recommended primarily for general health.

• Eating a balanced diet: Adequate protein, iron (ferritin), zinc, vitamin B12, and vitamin D support healthy hair growth. Nutritional testing should be guided by clinical history and examination rather than undertaken routinely.

Patients should always inform their GP or pharmacist of any supplements or herbal remedies they are taking. Some products — including saw palmetto, and lavender and tea tree oils — have been associated with hormonal activity in limited case reports, primarily in prepubertal boys; evidence of clinically significant effects in adults is limited. Patients should discuss any such products with a healthcare professional before use.

From a clinical safety perspective, any suspected adverse effects from prescribed medicines — including those affecting breast tissue or hair — should be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk). Regular follow-up with a GP or specialist is important to monitor treatment response and adjust management as needed.

Finally, the psychological impact of gynaecomastia and hair loss should not be underestimated. Both conditions can cause significant distress, and patients may benefit from psychological support or referral to relevant patient support groups. NHS Talking Therapies and condition-specific charities — including the British Association of Dermatologists patient information resources — can provide valuable additional support alongside medical management.

Sources: NHS – Hair loss; NHS – Alcohol advice; British Association of Dermatologists – patient information (male pattern hair loss; alopecia areata); MHRA Yellow Card Scheme.

Frequently Asked Questions